<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999569</url>
  </required_header>
  <id_info>
    <org_study_id>LH-2013</org_study_id>
    <nct_id>NCT01999569</nct_id>
  </id_info>
  <brief_title>The Role of Estrogen in Luteinizing Hormone Surge and Ovulation</brief_title>
  <official_title>The Role of Estrogen in Luteinizing Hormone Surge and Ovulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to establish that sustained estrogen levels are the driving force&#xD;
      for the LH surge, and are thereby necessary for ovulation to occur. We predict that by&#xD;
      reducing levels of circulating estrogen, letrozole, an aromatase inhibitor, will inhibit&#xD;
      ovulation from occurring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sine the common understanding of ovulation in a natural cycle suggests that a sustained,&#xD;
      elevated estradiol level is required to trigger the LH surge, administration of letrozole&#xD;
      throughout the cycle should lower estradiol levels and prevent the LH surge from occurring.&#xD;
      In this study, we sought to determine if the LH surge, ovulation and luteinization occurs in&#xD;
      spite of low estradiol levels by daily administration of letrozole in a group of normal&#xD;
      ovulatory volunteers in a prospective study.&#xD;
&#xD;
      After IRB approval and informed consent were obtained, ten willing volunteers that met&#xD;
      inclusion criteria (no hormonal contraception within 3 months, regular menstrual cycles 26 -&#xD;
      30 days, normal thyroid function and normal prolactin, and no pregnancy currently or within 3&#xD;
      months) were monitored for one month without treatment for evaluation of normal ovulation.&#xD;
&#xD;
      Natural control cycle The subjects used home urine LH tests (Clearblue® Easy, SPD Swiss&#xD;
      Precision Diagnostics, Switzerland) on days 10-18 to monitor for the LH surge in both the&#xD;
      initial natural cycle and the letrozole cycle. Blood was drawn every other day starting on&#xD;
      day 12 of the cycle through day 22 to measure estradiol and progesterone levels, and&#xD;
      follicular development was monitored using transvaginal ultrasound on cycle day 12-14.&#xD;
&#xD;
      Letrozole cycle In the next cycle, all ten subjects were administered oral letrozole 5 mg&#xD;
      daily (Femara®, Novartis Pharmaceuticals Corporation, East Hanover, NJ ) starting on cycle&#xD;
      day 1-3 and continuing through the completion of the study (cycle day 22). Once again, serum&#xD;
      estradiol and progesterone levels were measured every other day on days 12-22. The&#xD;
      development of the ovarian follicles was monitored by transvaginal ultrasound once in each&#xD;
      cycle between days 12-14, and LH surge was monitored with home urine ovulation tests on days&#xD;
      10-18. Table 1 illustrates protocols for both the natural control cycle and the letrozole&#xD;
      study cycle.&#xD;
&#xD;
      The primary outcome, assessment of ovulation in letrozole cycles, was determined by the&#xD;
      presence or absence of progesterone elevation (&gt;1.5 ng/mL) and the presence or absence of a&#xD;
      positive urinary LH test. The bioequivalence evaluation of two cycles (before and after&#xD;
      letrozole administration) was based on pharmacokinetic parameters such as area under the&#xD;
      serum concentration-time curve (AUC), the peak serum concentration (Cmax) and the time of&#xD;
      peak serum concentration (Tmax). Cmax and Tmax were determined by visual inspection from each&#xD;
      volunteer's serum concentration-time curve for estradiol and progesterone. AUC was calculated&#xD;
      by the linear trapezoidal method from day 12 through day 22 in both the initial natural cycle&#xD;
      and the letrozole cycle.&#xD;
&#xD;
      Paired t-tests, or Wilcoxon Signed Rank tests if non-normally distributed, were used to&#xD;
      evaluate the statistical significance of the mean values of the pharmacokinetic parameters.&#xD;
      The McNemar test was used to assess the difference in LH surge and follicular development&#xD;
      before and after letrozole administration. A standard of statistical significance (alpha) of&#xD;
      0.05 was used in all cases. The SAS System (SAS Institute, Cary, NC) was used for all&#xD;
      analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Progesterone Level Greater Than 1.5 ng/mL</measure>
    <time_frame>Cycle days 12-22</time_frame>
    <description>Serum progesterone ng/mL drawn during cycle days twelve through 22</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Positive LH Test</measure>
    <time_frame>Cycle days 10-18</time_frame>
    <description>Urine ovulation tests assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Follicular Development</measure>
    <time_frame>Cycle day 12</time_frame>
    <description>Ovulation; elevated progesterone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Ovulation Disorder</condition>
  <condition>Ovarian Cysts</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control cycle. No intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole administered daily through the time of ovulation.</description>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient having regular menstrual cycles between 26-30 days&#xD;
&#xD;
          -  Ages 18-40&#xD;
&#xD;
          -  Patient must not be sexually active during the study period, or if so must be using a&#xD;
             reliable form of non-hormonal birth control including tubal ligation or vasectomy,&#xD;
             non-hormonal intrauterine contraceptive device (IUD), or condoms with spermicide.&#xD;
&#xD;
          -  Willing to participate in study and available for all monitoring visits.&#xD;
&#xD;
          -  IRB consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient must NOT have used hormonal contraception three months or less prior to study.&#xD;
&#xD;
          -  Irregular menstrual cycles (&lt;26 days or &gt;30 days within the last 6 months.&#xD;
&#xD;
          -  Untreated thyroid dysfunction or hyperprolactinemia&#xD;
&#xD;
          -  Pregnancy (current or within 3 months) or breastfeeding&#xD;
&#xD;
          -  Allergy or contraindication to letrozole&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brad S Hurst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atrium Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Institute at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Christensen A, Bentley GE, Cabrera R, Ortega HH, Perfito N, Wu TJ, Micevych P. Hormonal regulation of female reproduction. Horm Metab Res. 2012 Jul;44(8):587-91. doi: 10.1055/s-0032-1306301. Epub 2012 Mar 21. Review.</citation>
    <PMID>22438212</PMID>
  </reference>
  <reference>
    <citation>Morioka N, Zhu C, Brännström M, Woessner JF, LeMaire WJ. Mechanism of mammalian ovulation. Prog Clin Biol Res. 1989;294:65-85. Review.</citation>
    <PMID>2657783</PMID>
  </reference>
  <reference>
    <citation>Goh HH, Ratnam SS. The LH surge in humans: its mechanism and sex difference. Gynecol Endocrinol. 1988 Jun;2(2):165-82. Review.</citation>
    <PMID>3055821</PMID>
  </reference>
  <reference>
    <citation>Laven JS, Fauser BC. What role of estrogens in ovarian stimulation. Maturitas. 2006 Jul 20;54(4):356-62. Epub 2006 Jun 19. Review.</citation>
    <PMID>16782289</PMID>
  </reference>
  <reference>
    <citation>Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab. 2006 Mar;91(3):760-71. Epub 2005 Dec 29. Review.</citation>
    <PMID>16384846</PMID>
  </reference>
  <reference>
    <citation>Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig. 2004 Sep;11(6):406-15.</citation>
    <PMID>15350255</PMID>
  </reference>
  <reference>
    <citation>Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010 Sep;6(5):243-6. doi: 10.1200/JOP.000082. Epub 2010 Aug 6.</citation>
    <PMID>21197188</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <results_first_submitted>February 9, 2015</results_first_submitted>
  <results_first_submitted_qc>October 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Brad Hurst</investigator_full_name>
    <investigator_title>Director of Assisted Reproduction</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Ovulatory volunteers</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Then Letrozole</title>
          <description>Control cycle. Then letrozole cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Control Cycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">First cycle no meds</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Letrozole Treatment Cycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Control cycle. Then letrozole cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Progesterone Level Greater Than 1.5 ng/mL</title>
        <description>Serum progesterone ng/mL drawn during cycle days twelve through 22</description>
        <time_frame>Cycle days 12-22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control cycle</description>
          </group>
          <group group_id="O2">
            <title>Letrozole Treatment Cycle</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progesterone Level Greater Than 1.5 ng/mL</title>
          <description>Serum progesterone ng/mL drawn during cycle days twelve through 22</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Positive LH Test</title>
        <description>Urine ovulation tests assessed</description>
        <time_frame>Cycle days 10-18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control cycle</description>
          </group>
          <group group_id="O2">
            <title>Letrozole Treatment Cycle</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive LH Test</title>
          <description>Urine ovulation tests assessed</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Follicular Development</title>
        <description>Ovulation; elevated progesterone</description>
        <time_frame>Cycle day 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control cycle.</description>
          </group>
          <group group_id="O2">
            <title>Letrozole Treatment Cycle</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Follicular Development</title>
          <description>Ovulation; elevated progesterone</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>two ovulation cycles (2 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Control cycle. No intervention.</description>
        </group>
        <group group_id="E2">
          <title>Letrozole</title>
          <description>5mg daily&#xD;
Letrozole: Letrozole administered daily through the time of ovulation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bradley Hurst, M.D., Director of Assisted Reproduction</name_or_title>
      <organization>Carolinas Healthcare System</organization>
      <phone>704-355-3149</phone>
      <email>bhurst@carolinas.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

